Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Animals
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Cell Communication
/ immunology
Dendritic Cells
/ drug effects
Disease Models, Animal
Humans
Immune Checkpoint Inhibitors
/ pharmacology
Immunotherapy
/ methods
Lymphocytes, Tumor-Infiltrating
/ drug effects
Neoplasms
/ drug therapy
T-Lymphocytes
/ drug effects
Tumor Microenvironment
/ drug effects
Wnt Signaling Pathway
/ drug effects
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 08 2020
01 08 2020
Historique:
received:
22
01
2020
revised:
16
03
2020
accepted:
21
04
2020
pubmed:
26
4
2020
medline:
3
11
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
The development of the most successful cancer immunotherapies in solid tumors, immune-checkpoint blockade, has focused on factors regulating T-cell activation. Until recently, the field has maintained a predominately T-cell centric view of immunotherapy, leaving aside the impact of innate immunity and especially myeloid cells. Dendritic cells (DC) are dominant partners of T cells, necessary for initiation of adaptive immune responses. Emerging evidence supports a broader role for DCs in tumors including the maintenance and support of effector functions during T-cell responses. This relationship is evidenced by the association of activated DCs with immune-checkpoint blockade responses and transcriptional analysis of responding tumors demonstrating the presence of type I IFN transcripts and DC relevant chemokines. T-cell-inflamed tumors preferentially respond to immunotherapies compared with non-T-cell-inflamed tumors and this model suggests a potentially modifiable spectrum of tumor microenvironmental immunity. Although host and commensal factors may limit the T-cell-inflamed phenotype, tumor cell intrinsic factors are gaining prominence as therapeutic targets. For example, tumor WNT/β-catenin signaling inhibits production of chemokine gradients and blocking DC recruitment to tumors. Conversely, mechanisms of innate immune nucleic acid sensing, normally operative during pathogen response, may enhance DC accumulation and make tumors more susceptible to cancer immunotherapy. Elucidating mechanisms whereby DCs infiltrate and become activated within tumors may provide new opportunities for therapeutic intervention. Conceptually, this would facilitate conversion of non-T-cell-inflamed to T-cell-inflamed states or overcome secondary resistance mechanisms in T-cell-inflamed tumors, expanding the proportion of patients who benefit from cancer immunotherapy.
Identifiants
pubmed: 32332013
pii: 1078-0432.CCR-19-1321
doi: 10.1158/1078-0432.CCR-19-1321
pmc: PMC7607412
mid: NIHMS1586749
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3901-3907Subventions
Organisme : NCI NIH HHS
ID : F32 CA250147
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA179265
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Vaccine. 2009 Mar 26;27(15):2177-87
pubmed: 19201385
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Cancer Cell. 2018 Jan 8;33(1):60-74.e6
pubmed: 29316433
Cancer Cell. 2017 May 8;31(5):711-723.e4
pubmed: 28486109
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Science. 2018 Feb 16;359(6377):770-775
pubmed: 29301958
Nat Rev Immunol. 2020 Jan;20(1):7-24
pubmed: 31467405
Cancer Immunol Res. 2019 Jan;7(1):29-39
pubmed: 30482745
Nat Med. 2019 May;25(5):814-824
pubmed: 30962585
Front Immunol. 2019 Jan 28;10:41
pubmed: 30745902
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Science. 2017 Jun 9;356(6342):
pubmed: 28473638
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Blood. 2008 Feb 15;111(4):1942-5
pubmed: 18055870
Nat Med. 2018 Aug;24(8):1178-1191
pubmed: 29942093
Immunol Rev. 2019 Jul;290(1):24-38
pubmed: 31355488
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Annu Rev Immunol. 2013;31:563-604
pubmed: 23516985
J Clin Invest. 2017 Apr 3;127(4):1425-1437
pubmed: 28319047
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768
pubmed: 27837020
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Cancer Cell. 2016 Aug 8;30(2):324-336
pubmed: 27424807
Immunity. 2014 Nov 20;41(5):843-52
pubmed: 25517616
Cancer Discov. 2019 Aug;9(8):1124-1141
pubmed: 31186238
Sci Transl Med. 2020 Mar 11;12(534):
pubmed: 32161104
J Exp Med. 2018 May 7;215(5):1287-1299
pubmed: 29622565
Sci Immunol. 2019 Sep 13;4(39):
pubmed: 31519811
Nat Rev Immunol. 2014 Aug;14(8):571-8
pubmed: 25033907
J Exp Med. 2017 Aug 7;214(8):2231-2241
pubmed: 28663435
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Immunity. 2017 Feb 21;46(2):205-219
pubmed: 28190711
J Immunol. 1994 Aug 15;153(4):1697-706
pubmed: 7913943
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Immunity. 2006 Jul;25(1):153-62
pubmed: 16860764
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
Cancer Immunol Res. 2018 Sep;6(9):990-1000
pubmed: 30181337
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Immunity. 2013 Jul 25;39(1):38-48
pubmed: 23890062
Clin Cancer Res. 2019 May 15;25(10):3074-3083
pubmed: 30635339
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Nature. 2019 Jan;565(7737):43-48
pubmed: 30559380
Immunity. 2016 Oct 18;45(4):719-736
pubmed: 27760337
J Clin Invest. 2007 May;117(5):1195-203
pubmed: 17476349
Cell. 2019 Apr 18;177(3):556-571.e16
pubmed: 30955881
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Sci Immunol. 2019 Mar 1;4(33):
pubmed: 30824528
Annu Rev Immunol. 2000;18:245-73
pubmed: 10837059
Nature. 2005 Aug 25;436(7054):1186-90
pubmed: 15995699
Genome Med. 2020 Oct 27;12(1):90
pubmed: 33106165
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Science. 2018 Nov 9;362(6415):694-699
pubmed: 30409884
Nat Med. 2019 Mar;25(3):454-461
pubmed: 30804515
Nat Immunol. 2015 Jul;16(7):708-17
pubmed: 26054719
Nature. 2017 May 4;545(7652):98-102
pubmed: 28445461
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
Nat Med. 2018 Nov;24(11):1649-1654
pubmed: 30297909
Nat Med. 2018 Aug;24(8):1192-1203
pubmed: 29988124
Clin Cancer Res. 2020 Jan 15;26(2):487-504
pubmed: 31636098
Science. 2015 Oct 30;350(6260):568-71
pubmed: 26405230
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Nat Rev Immunol. 2017 Jan;17(1):30-48
pubmed: 27890914
Cancer Immunol Res. 2016 Jul;4(7):563-8
pubmed: 27197067
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Immunity. 2016 Apr 19;44(4):924-38
pubmed: 27096321
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Cancer Discov. 2016 Jan;6(1):71-9
pubmed: 26493961
Cancer Discov. 2019 Jan;9(1):34-45
pubmed: 30297358
Nature. 2015 Jul 9;523(7559):231-5
pubmed: 25970248
Nat Med. 2018 Nov;24(11):1655-1661
pubmed: 30297911
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8670-5
pubmed: 15163797
Cancer Immunol Res. 2014 Jan;2(1):80-90
pubmed: 24778163
Nat Med. 2016 Dec;22(12):1402-1410
pubmed: 27775706
Cell. 2018 Feb 22;172(5):1022-1037.e14
pubmed: 29429633
Cell. 2015 Sep 10;162(6):1257-70
pubmed: 26343581
Immunity. 2018 Dec 18;49(6):1148-1161.e7
pubmed: 30552023